Myriad Genetics Buys Sividon Diagnostics

Salt Lake City-based Myriad Genetics has acquired Sividon Diagnostics, a developer of diagnostic test for breast cancer, the company said Tuesday afternoon. Myriad Genetics said it paid EUR 35M upfront, plus up to EUR 15M in additional, performance-based milestones for Sividon. Sividon Diagnostics is a spinout of Siemens Healthcare Diagnotics, and current provides RNA expression tests of genes to assess the aggressiveness of breast cancer.